EGFR and non-small cell lung carcinoma: Another study HS-10296-306 (NCT04923906) is designed to evaluate the safety and efficacy of aumolertinib, a third generation EGFR-TKI, in combination with chemotherapy in the treatment of locally advanced or metastatic NSCLC with sensitizing EGFR mutations, when compared to aumolertinib alone (Table 1).